Table 1.

Key oncogenic targets in melanoma

Oncogene/pathwayDrug targetDrugs in clinical development
cKITcKITImatinib, nilotinib, sunitinib, dasatinib
NRASMEK, PI3K, AKT, mTORGSK112212, AZD6244, GDC0941, MK2206, temsirolimus
BRAFBRAF, MEKVemurafenib, GSK2118436
PI3KPI3K, AKT, mTORGDC0941, GSK2126458, BEZ235, BKM120, XL765, XL147, MK2206, GSK690693, temsirolimus
MITFCDK2, HDACSCH727965, panobinostat
p16/CDK4CDK4PD0332991, LY2835219
p53mdm2RG7112

NOTE: Oncogenes (or their pathways), drug targets, and actual drugs in clinical development are listed (as labeled). This list is not exhaustive, but it provides examples of both direct and indirect targeting strategies for advanced melanoma.